Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · APRE · as of Sep 30, 2025
Ownership Breakdown
23
Institutional Holders
$2.39M
Total Inst. Value
▼ $684,526 vs Q2
6.49M
Shares Outstanding
freeFloat 74.68%
1.62M
13F Shares Held
▼ 196,657 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
APRE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
AIGH CAPITAL MANAGEMENT LLC pharmaceutical preparations | 539.3K | 8.87% | 8.87% | $795.47M | Oct 31, 2025 | — held |
SPHERA FUNDS MANAGEMENT LTD. pharmaceutical preparations | 270.0K | 4.44% | 4.44% | $398.25M | Nov 14, 2025 | — held |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 205.8K | 3.38% | 3.38% | $303.50M | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 158.2K | 2.60% | 2.60% | $233.40M | Nov 7, 2025 | ▼ 15.6K |
DAFNA CAPITAL MANAGEMENT LLC pharmaceutical preparations | 137.2K | 2.25% | 2.25% | $202.33M | Nov 14, 2025 | — held |
SIO CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 112.2K | 1.84% | 1.84% | $165.53M | Nov 13, 2025 | ▼ 167.1K |
MORGAN STANLEY pharmaceutical preparations | 65.8K | 1.08% | 1.08% | $97.07M | May 27, 2026 | ▲ 2.5K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 44.6K | 73.34% | 73.34% | $65.82M | Nov 12, 2025 | ▲ 1.5K |
BNP PARIBAS ARBITRAGE, SNC pharmaceutical preparations | 17.1K | 28.16% | 28.16% | $25.27M | Nov 13, 2025 | ▲ 1.7K |
LPL FINANCIAL LLC pharmaceutical preparations | 16.1K | 26.39% | 26.39% | $23.68M | Nov 12, 2025 | ▼ 1.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
5
Increased
+5.7K shares2
New Positions
first time holders6
Decreased
−199.6K shares2
Sold Out
fully exitedNet shares change (top 50)
194.0K
+5.7K / −199.6K
Net new holders
-1
2 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
APRE insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
12
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Mar 31, 2026 | Purchase | 30,978 | $0.00 | $30.978 | 31.0K | Form 4 ↗ |
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Mar 31, 2026 | Purchase | 30,978 | $0.68 | $21.2K | 31.0K | Form 4 ↗ |
Peters Richard director | Mar 31, 2026 | Purchase | 123,915 | $0.00 | $123.915 | 123.9K | Form 4 ↗ |
Peters Richard director | Mar 31, 2026 | Purchase | 123,915 | $0.68 | $84.6K | 123.9K | Form 4 ↗ |
Gilad Oren President/CEO | Mar 12, 2026 | Award | 20,175 | — | — | 393.9K | Form 4 ↗ |
Gilad Oren President/CEO | Mar 12, 2026 | Award | 80,700 | $0.77 | $61.7K | 80.7K | Form 4 ↗ |
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Mar 12, 2026 | Award | 10,095 | — | — | 43.5K | Form 4 ↗ |
Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Mar 12, 2026 | Award | 40,380 | $0.77 | $30.9K | 40.4K | Form 4 ↗ |
Gilad Oren President/CEO | Jan 30, 2026 | Purchase | 28,100 | $0.89 | $25.0K | 373.7K | Form 4 ↗ |
Gilad Oren President/CEO | Jan 30, 2026 | Purchase | 28,100 | $0.77 | $21.5K | 28.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aprea Therapeutics, Inc. (APRE) is primarily owned by institutional investors, who hold approximately 24.9% of total shares outstanding. Company insiders own approximately 25.32%, while retail and public investors account for the remaining 49.75%.
The largest institutional shareholder of Aprea Therapeutics, Inc. is AIGH CAPITAL MANAGEMENT LLC, holding approximately 539,300 shares — equal to 8.87% of outstanding shares — as of September 30, 2025.
A total of 23 institutional investors currently hold APRE stock, with a combined institutional value of approximately $2,387,744 as of the most recent 13F filing period.
Frequently asked questions
APRE ownershipAprea Therapeutics, Inc. (APRE) is primarily owned by institutional investors, who hold approximately 24.9% of shares. The largest shareholder is AIGH CAPITAL MANAGEMENT LLC with a 8.87% stake. Company insiders hold 25.32%. Data sourced from SEC Form 13F as of September 30, 2025.